According to the new market research report “Non-Invasive Prenatal Testing Market by Instruments (Ultrasound, NGS, PCR, Microarray), Consumables, Method (FCMB, cf-DNA), Application (Trisomy, Microdeletion, Genetics, Rh factor) & End User (Hospital, Diagnostic Labs) - Global Forecast to 2021", published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia, and the Rest of the World (RoW).
Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690
The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period. Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.
Key Players in the Global NIPT Market
The NIPT market is diversified and highly competitive, with a large number of players competing for market space. The prominent players in the market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK)
Inquire or share your questions if any before the purchasing this report
: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=145607690
Growth prospects in Non Invasive Prenatal Testing (NIPT) Market :
The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period. Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.
By method, the NIPT products market is segmented into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests. The cfDNA in maternal plasma tests segment is expected to grow at the highest CAGR during the forecast period.
Based on application, the non-invasive prenatal testing (NIPT) market is segmented into trisomy, microdeletion syndrome, and other applications (gender identification and the detection of monogenic disorders, Klinefelter syndrome, and Rhesus (Rh) blood type). In 2018, trisomy was the largest application segment of the NIPT market.
Based on end user, the NIPT products market is classified into diagnostic laboratories and hospitals. In 2019, diagnostic laboratories formed the largest and fastest-growing end users of NIPT products.
Non Invasive Prenatal Testing (NIPT) :Latest Trends & Industry Vision by 2024
For instance, in December 2020, Natera extended its coverage from the biggest U.S. Health Plan named Aetna with respect to its NIPT, covering every type of pregnancy.Free Sample Copy with Considering Coivd19 Impact on this Market @ https://www.marketresearchfuture.com/sample_request/8371NIPT is increasingly being used among patients above the age of 35 experiencing high-risk pregnancies.
Companies are constantly striving to develop advanced NIPT solutions to bolster their sales, in order to remain competitive in the global market.
Market Segmentation To offer a comprehensive framework of the non-invasive prenatal testing industry, the MRFR report has outlined a few major segments, namely product type, techniques, application, and end-user.
Diagnostic laboratories form the biggest segment in the market as a large number of these facilities offer NIPT testing devices as well as services.Regional Status The global industry has been regionally considered for Asia Pacific/APAC and MEA or Middle East & Africa coupled with the Americas as well as Europe.The American market stands at the top spot and is expected to maintain its lead throughout the analysis period.
Since several global players are gaining entry into Asia Pacific, sensing the host of lucrative opportunities, it is believed that the regional market will progress at the fastest rate in the years to come.
With companies like BGI present in China, the APAC market is bound to exhibit commendable growth in subsequent years.Prominent Contenders General Electric Company [GE Healthcare] (US), Perkinelmer, Inc. (US), Illumina, Inc. (US), Beijing Genomics Institute (China), Thermo Fisher Scientific, Inc. (US), Tarsa Therapeutics Inc. (US), PhytoHealth Corporation (Taiwan), Laboratory Corporation of America Holdings (US), Hoffman-La Roche Ltd. (Switzerland), Yourgene Health (UK), Centogene Holding AG [CENTOGENE AG] (Germany), Natera, Inc. (US), Agilent Technologies, Inc. (US), are some of the top companies in the non-invasive prenatal testing industry.
It involves the testing for particular diseases or birth defects in a fetus or embryo before it is born.Statistics:The global non-invasive prenatal testing market is estimated to account for US$ 1,936.4 Mn in terms of value by the end of 2027.Global Non-Invasive Prenatal Testing Market: DriversHigh prevalence of chromosomal disorders is expected to propel growth of the global non-invasive prenatal testing market over the forecast period.
Obstetricians are increasingly recommending patients to undergo non-invasive tests as an alternative to invasive methods and initial diagnostic screening in the first trimester of a pregnancy.Statistics:North America held dominant position in the global non-invasive prenatal testing market in 2019, accounting for 45% share in terms of value, followed by Europe and Asia Pacific, respectively.Get PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/579Global Non-Invasive Prenatal Testing Market: RestraintsUncertain reimbursement policies and insurance coverage is expected to hinder growth of the global non-invasive prenatal testing market.
Given the high costs for these tests, most vendors enjoy limited success due to limited or no coverage for these tests.Moreover, tests are patented by select few vendors, which is also expected to limit growth of the market.
As a result, there is limited market competition and limited incentive to reduce cost of testing, as well as quality assurance.Global Non-Invasive Prenatal Testing Market: OpportunitiesObtaining reimbursement for tests from payers is expected to offer lucrative growth opportunities for players in the global non-invasive prenatal testing market.
Vendors may focus on obtaining insurance coverage for NIPT tests offered by them, considering the high costs of these tests.Moreover, attention towards health education, subsidies for NIPT, and genetic counseling is also expected to aid in growth of the market.
For instance, in September 2020, researchers from Fudan University, China, and University College London, U.K., reported that, in China, compared with Zhengzhou participants, a higher proportion of Shenzhen women had heard of NIPT (87.30% vs. 64.03%), were willing to receive NIPT (91.80% vs. 80.43%) and had taken NIPT (83.12% vs. 54.54%), while their satisfaction level was lower.Statistics:The global non-invasive prenatal testing market was valued at US$ 882.9 Mn in 2019 and is forecast to reach a value of US$ 1,936.4 Mn by 2027 at a CAGR of 10.3% between 2020 and 2027.Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/579Market Trends/Key TakeawaysRecommendation of new guidelines is expected to propel growth of the global non-invasive prenatal testing market over the forecast period.
Small DNA fragments in the mother's blood are used to identify particular genetic material (genetic material that defines the makeup of the human cell and protein building blocks).
Every mother's blood contains these tiny particles.Non-invasive prenatal testing (NIPT) exams have produced sufficient data to demonstrate their effectiveness.
The technique has been shown to be both effective and safe for the unborn child, and it has also been shown to help reduce the chances of premature birth and fetal abnormalities.
Certain institutions, however, continue to follow strict rules, as certain research show that NIPT testing might result in false positive findings.
When the mother's blood samples are examined during in vitro fertilization, non-invasive prenatal testing (NIPT) is used to determine the fetus' DNA or genetic make-up using non-invasive techniques.
If they're the same, the infant is considered normal.
TheBusinessResearchCompany published its Non-invasive Prenatal Testing Global Market Report 2020 which provides strategists, marketers and senior management with the critical information they need to assess the global non-invasive prenatal testing market.
The report covers the non-invasive prenatal testing market’s segments- consumables, instruments, hospital, diagnostic labs, NGS systems, PCR instruments, microarrays, ultrasound devices, others (centrifuges, UV systems, incubators, microscopes), assay kits , disposables, trisomy, microdeletion, genetics, Rh factor.Explore Complete Report https://www.thebusinessresearchcompany.com/report/non-invasive-prenatal-testing-global-market-reportNon-invasive Prenatal Testing Global Market Report 2020 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country.
It covers all the regions, key developed countries and major emerging markets.
The major regions included in the report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.Request to get the sample of this report https://www.thebusinessresearchcompany.com/sample.aspx?id=2492=smpNext generation sequencing has increased the throughput, scalability, speed, and further enables researchers to perform a wide range of applications and study biological systems at a higher level.
The manufacturers have introduced this technology to reduce the time and money required, and optimizes the output to generate results regarding genome and DNA testing.Get Discount On This Report https://www.thebusinessresearchcompany.com/sample.aspx?id=2492=discountChapters from Table of Content:Chapter 1.
It involves the testing for particular diseases or birth defects in a fetus or embryo before it is born.Statistics:The global non-invasive prenatal testing market is estimated to account for US$ 1,936.4 Mn in terms of value by the end of 2027.Global Non-Invasive Prenatal Testing Market: DriversHigh prevalence of chromosomal disorders is expected to propel growth of the global non-invasive prenatal testing market over the forecast period.
Obstetricians are increasingly recommending patients to undergo non-invasive tests as an alternative to invasive methods and initial diagnostic screening in the first trimester of a pregnancy.Statistics:North America held dominant position in the global non-invasive prenatal testing market in 2019, accounting for 45% share in terms of value, followed by Europe and Asia Pacific, respectively.Get PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/579Global Non-Invasive Prenatal Testing Market: RestraintsUncertain reimbursement policies and insurance coverage is expected to hinder growth of the global non-invasive prenatal testing market.
Given the high costs for these tests, most vendors enjoy limited success due to limited or no coverage for these tests.Moreover, tests are patented by select few vendors, which is also expected to limit growth of the market.
As a result, there is limited market competition and limited incentive to reduce cost of testing, as well as quality assurance.Global Non-Invasive Prenatal Testing Market: OpportunitiesObtaining reimbursement for tests from payers is expected to offer lucrative growth opportunities for players in the global non-invasive prenatal testing market.
Vendors may focus on obtaining insurance coverage for NIPT tests offered by them, considering the high costs of these tests.Moreover, attention towards health education, subsidies for NIPT, and genetic counseling is also expected to aid in growth of the market.
For instance, in September 2020, researchers from Fudan University, China, and University College London, U.K., reported that, in China, compared with Zhengzhou participants, a higher proportion of Shenzhen women had heard of NIPT (87.30% vs. 64.03%), were willing to receive NIPT (91.80% vs. 80.43%) and had taken NIPT (83.12% vs. 54.54%), while their satisfaction level was lower.Statistics:The global non-invasive prenatal testing market was valued at US$ 882.9 Mn in 2019 and is forecast to reach a value of US$ 1,936.4 Mn by 2027 at a CAGR of 10.3% between 2020 and 2027.Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/579Market Trends/Key TakeawaysRecommendation of new guidelines is expected to propel growth of the global non-invasive prenatal testing market over the forecast period.
For instance, in December 2020, Natera extended its coverage from the biggest U.S. Health Plan named Aetna with respect to its NIPT, covering every type of pregnancy.Free Sample Copy with Considering Coivd19 Impact on this Market @ https://www.marketresearchfuture.com/sample_request/8371NIPT is increasingly being used among patients above the age of 35 experiencing high-risk pregnancies.
Companies are constantly striving to develop advanced NIPT solutions to bolster their sales, in order to remain competitive in the global market.
Market Segmentation To offer a comprehensive framework of the non-invasive prenatal testing industry, the MRFR report has outlined a few major segments, namely product type, techniques, application, and end-user.
Diagnostic laboratories form the biggest segment in the market as a large number of these facilities offer NIPT testing devices as well as services.Regional Status The global industry has been regionally considered for Asia Pacific/APAC and MEA or Middle East & Africa coupled with the Americas as well as Europe.The American market stands at the top spot and is expected to maintain its lead throughout the analysis period.
Since several global players are gaining entry into Asia Pacific, sensing the host of lucrative opportunities, it is believed that the regional market will progress at the fastest rate in the years to come.
With companies like BGI present in China, the APAC market is bound to exhibit commendable growth in subsequent years.Prominent Contenders General Electric Company [GE Healthcare] (US), Perkinelmer, Inc. (US), Illumina, Inc. (US), Beijing Genomics Institute (China), Thermo Fisher Scientific, Inc. (US), Tarsa Therapeutics Inc. (US), PhytoHealth Corporation (Taiwan), Laboratory Corporation of America Holdings (US), Hoffman-La Roche Ltd. (Switzerland), Yourgene Health (UK), Centogene Holding AG [CENTOGENE AG] (Germany), Natera, Inc. (US), Agilent Technologies, Inc. (US), are some of the top companies in the non-invasive prenatal testing industry.
Small DNA fragments in the mother's blood are used to identify particular genetic material (genetic material that defines the makeup of the human cell and protein building blocks).
Every mother's blood contains these tiny particles.Non-invasive prenatal testing (NIPT) exams have produced sufficient data to demonstrate their effectiveness.
The technique has been shown to be both effective and safe for the unborn child, and it has also been shown to help reduce the chances of premature birth and fetal abnormalities.
Certain institutions, however, continue to follow strict rules, as certain research show that NIPT testing might result in false positive findings.
When the mother's blood samples are examined during in vitro fertilization, non-invasive prenatal testing (NIPT) is used to determine the fetus' DNA or genetic make-up using non-invasive techniques.
If they're the same, the infant is considered normal.
TheBusinessResearchCompany published its Non-invasive Prenatal Testing Global Market Report 2020 which provides strategists, marketers and senior management with the critical information they need to assess the global non-invasive prenatal testing market.
The report covers the non-invasive prenatal testing market’s segments- consumables, instruments, hospital, diagnostic labs, NGS systems, PCR instruments, microarrays, ultrasound devices, others (centrifuges, UV systems, incubators, microscopes), assay kits , disposables, trisomy, microdeletion, genetics, Rh factor.Explore Complete Report https://www.thebusinessresearchcompany.com/report/non-invasive-prenatal-testing-global-market-reportNon-invasive Prenatal Testing Global Market Report 2020 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country.
It covers all the regions, key developed countries and major emerging markets.
The major regions included in the report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.Request to get the sample of this report https://www.thebusinessresearchcompany.com/sample.aspx?id=2492=smpNext generation sequencing has increased the throughput, scalability, speed, and further enables researchers to perform a wide range of applications and study biological systems at a higher level.
The manufacturers have introduced this technology to reduce the time and money required, and optimizes the output to generate results regarding genome and DNA testing.Get Discount On This Report https://www.thebusinessresearchcompany.com/sample.aspx?id=2492=discountChapters from Table of Content:Chapter 1.